How many drugs treat Pediculosis capitis?

Drug Landscape tracks 7 marketed treatments for Pediculosis capitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pediculosis-capitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pediculosis capitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pediculosis capitis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pediculosis capitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xeglyze	ABAMETAPIR	Hatchtech		C-C chemokine receptor type 5	2020-01-01
Natroba	SPINOSAD	Cipher	Pediculicide [EPC]		2011-01-01
Ovide	MALATHION	Taro	Cholinesterase Inhibitor [EPC]	Melatonin receptor type 1A	1982-01-01
Lignospan Forte	Lidocaine Hydrochloride	Fresenius Kabi	local anesthetic, amide type	neuronal membrane ionic channels	1948-01-01
Lignocaine	Lignocaine	University of Malaya		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lidocain	Lidocain	Bayer		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
xylocain	xylocain	Saint-Joseph University		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pediculosis capitis:

Cite this brief

Drug Landscape (2026). Pediculosis capitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pediculosis-capitis. Accessed 2026-06-10.

Pediculosis capitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing